Polymorphic variants of ADRB2, NR3C1, MDR1 genes as possible predictors of efficacy of combined therapy laba + ICS in patients with chronic obstructive pulmonary disease

The aim of the study was to analyze possible associations efficacy in combined therapy LABA + ICS in patients with chronic obstructive pulmonary disease (COPD) with genotypes for genes ADRB2 (A46G and C79G), NR3C1(C646G), MDR1(C3435T). These findings demonstrate the high efficiency of combined thera...

Full description

Saved in:
Bibliographic Details
Published inThe pharma innovation Vol. 3; no. 8, Part A; p. 10
Main Authors Gorovenko, N G, Stupnytska, G Y, Podolskaya, S V
Format Journal Article
LanguageEnglish
Published New Delhi The Pharma Innovation 01.10.2014
Subjects
Chronic obstructive pulmonary disease
Online AccessGet full text

Cover

More Information
Summary:The aim of the study was to analyze possible associations efficacy in combined therapy LABA + ICS in patients with chronic obstructive pulmonary disease (COPD) with genotypes for genes ADRB2 (A46G and C79G), NR3C1(C646G), MDR1(C3435T). These findings demonstrate the high efficiency of combined therapy LABA + ICS in patients with CC and CG genotypes for gene ADRB2 (C79G) and an increased risk of negative response on treatment in patients with genotype GG for gene ADRB2 (C79G), which indicates the possibility of using complex clinical data, results of instrumental, laboratory testing and genetic testing for predicting the effectiveness of treatment.
ISSN:2277-7695